ERBB2 and gastroesophageal junction adenocarcinoma: This study estimates the cost-effectiveness of ZOL-FO as a first-line regimen for the treatment ofCLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma compared with PLB-FO from the perspective of the Chinese healthcare system based on the results obtained from the SPOTLIGHT trial (Shitara et al., 2023).